Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C9H11N3O4 |
Molecular Weight | 225.2013 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 4 / 4 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]12OC3=NC(=N)C=CN3[C@]1([H])O[C@H](CO)[C@H]2O
InChI
InChIKey=BBDAGFIXKZCXAH-CCXZUQQUSA-N
InChI=1S/C9H11N3O4/c10-5-1-2-12-8-7(16-9(12)11-5)6(14)4(3-13)15-8/h1-2,4,6-8,10,13-14H,3H2/t4-,6-,7+,8-/m1/s1
Cyclocytidine HCl (also known as Ancitabine) is the prodrug of cytarabine, which is structurally similar to human deoxycytidine to be incorporated into human DNA and then kills the cell. Cyclocytidine was introduced as an antineoplastic agent for the treatment of lymphatic leukemia, sinus acceleration and an increase in systemic blood pressure. Cyclocytidine in combination with amsacrine were effective retrieval therapy for pediatric patients with acute nonlymphoblastic leukemia who were in relapse or unresponsive to frontline therapy.
Approval Year
PubMed
Title | Date | PubMed |
---|---|---|
Phase I. evaluation of cyclocytidine (NSC-145668). | 1975 Mar-Apr |
|
Letter: Myelotoxicity and orthostatic hypotension of cyclocytidine (NSC-145668). | 1976 Mar |
|
Antiviral activities of acyl derivatives of 2,2'-anhydro-1-beta-D-arabinofuranosylcytosine and 1-beta-D-arabinofuranosylcytosine in cell culture. | 1977 Feb |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/1707336
acute nonlymphoblastic leukemia: Induction therapy consisted of intravenous (IV) Amsacrine (75 mg/m2) from days 1 to 5 and subcutaneous cyclocytidine (600 mg/m2) from days 1 to 7.
Route of Administration:
Other
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C1557
Created by
admin on Fri Dec 15 17:35:52 GMT 2023 , Edited by admin on Fri Dec 15 17:35:52 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
D003504
Created by
admin on Fri Dec 15 17:35:52 GMT 2023 , Edited by admin on Fri Dec 15 17:35:52 GMT 2023
|
PRIMARY | |||
|
m1893
Created by
admin on Fri Dec 15 17:35:52 GMT 2023 , Edited by admin on Fri Dec 15 17:35:52 GMT 2023
|
PRIMARY | Merck Index | ||
|
74838
Created by
admin on Fri Dec 15 17:35:52 GMT 2023 , Edited by admin on Fri Dec 15 17:35:52 GMT 2023
|
PRIMARY | |||
|
25051
Created by
admin on Fri Dec 15 17:35:52 GMT 2023 , Edited by admin on Fri Dec 15 17:35:52 GMT 2023
|
PRIMARY | |||
|
DTXSID6020357
Created by
admin on Fri Dec 15 17:35:52 GMT 2023 , Edited by admin on Fri Dec 15 17:35:52 GMT 2023
|
PRIMARY | |||
|
31698-14-3
Created by
admin on Fri Dec 15 17:35:52 GMT 2023 , Edited by admin on Fri Dec 15 17:35:52 GMT 2023
|
PRIMARY | |||
|
100000086922
Created by
admin on Fri Dec 15 17:35:52 GMT 2023 , Edited by admin on Fri Dec 15 17:35:52 GMT 2023
|
PRIMARY | |||
|
74843
Created by
admin on Fri Dec 15 17:35:52 GMT 2023 , Edited by admin on Fri Dec 15 17:35:52 GMT 2023
|
PRIMARY | |||
|
3992
Created by
admin on Fri Dec 15 17:35:52 GMT 2023 , Edited by admin on Fri Dec 15 17:35:52 GMT 2023
|
PRIMARY | |||
|
SUB05507MIG
Created by
admin on Fri Dec 15 17:35:52 GMT 2023 , Edited by admin on Fri Dec 15 17:35:52 GMT 2023
|
PRIMARY | |||
|
DO2D32W0VC
Created by
admin on Fri Dec 15 17:35:52 GMT 2023 , Edited by admin on Fri Dec 15 17:35:52 GMT 2023
|
PRIMARY | |||
|
212
Created by
admin on Fri Dec 15 17:35:52 GMT 2023 , Edited by admin on Fri Dec 15 17:35:52 GMT 2023
|
PRIMARY | |||
|
CHEMBL1412614
Created by
admin on Fri Dec 15 17:35:52 GMT 2023 , Edited by admin on Fri Dec 15 17:35:52 GMT 2023
|
PRIMARY | |||
|
C80636
Created by
admin on Fri Dec 15 17:35:52 GMT 2023 , Edited by admin on Fri Dec 15 17:35:52 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)